摘要 |
The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32ndresidue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. |
申请人 |
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY;YEOM, YOUNG IL;SOHN, BO HWA;PARK, IN YOUNG;LEE, JUNG JU;JANG, YEJIN;YANG, SUK-JIN;PARK, KYUNG CHAN;YOO, HYANG-SOOK;CHOI, JONG YOUNG |
发明人 |
YEOM, YOUNG IL;SOHN, BO HWA;PARK, IN YOUNG;LEE, JUNG JU;JANG, YEJIN;YANG, SUK-JIN;PARK, KYUNG CHAN;YOO, HYANG-SOOK;CHOI, JONG YOUNG |